Hepatic Cellular Carcinoma
Conditions
Interventions
Trail group:pharmaceutical injection
Sponsors
Department of Nuclear Medicine, Peking University Cancer Hospital.
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 years old; ECOG 0 or 1; 2. Subjects who are clinically suspected of hepatocellular carcinoma or hepatocellular carcinoma who reoccurs after surgery/treatment; 3. Expected survival >=12 weeks; 4. Blood routine, liver and kidney function meet the following standards: Blood routine: WBC >=4.0x10^9/L or Neutrophils >=1.5x10^9/L; PLT >=100x10^9/LHb >=90g/L; PT or APTT <=1.5 ULN; Liver and kidney function: T-Bil <=1.5 ULN (Upper limit of normal), ALT/AST <=2.5 ULN or <=5 ULN (Subjects with liver metastases), ALP <=2.5 ULN (If there is bone metastasis or liver metastasis, ALP <=4.5 ULN); BUN <=1.5 ULN, SCr <=1.5 ULN; 5. There is at least one measurable target lesion according to the RECIST1.1 standard; 6. Women must use effective contraception during the study period and within 6 months after the study ends (Effective contraceptive measures refer to sterilization, hormonal devices, condoms, contraceptives/drugs, abstinence or partner removal of the vas deferens, etc.); Men should agree to subjects who must use contraception during the study period and within 6 months after the end of the study period; 7. Able to understand and voluntarily sign the informed consent form, with good compliance.
Exclusion criteria
Exclusion criteria: 1. Serious abnormal liver and kidney function; 2. Pregnancy, pregnant and lactating women; 3. Those who cannot lie down for half an hour; 4. Those who refuse to join this clinical researcher; 5. Suffer from claustrophobia or other mental illness; 6. Situations that other researchers consider unsuitable to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SUV; | — |
Countries
China
Contacts
Public ContactYang Zhi
Peking University Cancer Hospital and Institute
Outcome results
None listed